Abstract:Objectives: To study the differences between malignant hypermetabolic axillary lymphadenopathy (MHL) and COVID-19 vaccine-associated axillary hypermetabolic lymphadenopathy (VAHL) using clinical imaging. Methods: A total of 1096 patients underwent Positron Emission Tomography-Computed Tomography (PET-CT) between 1 June 2021 and 30 April 2022 at Ehime University Hospital. In total, 188 patients with axillary lymphadenopathy after the COVID-19 vaccination were evaluated. The patients were classified into three groups such as VAHL (n = 27), MHL (n = 21), and equivocal hypermetabolic axillary lymphadenopathy (EqHL; n = 140). Differences in lymph node (LN) swellings were statistically analyzed using clinical imaging (echography, CT, and 18F-FDG PET). Results: MHL included a higher female population (90.5%) owing to a higher frequency of breast cancer (80.9%). Axillary LNs of MHL did not show any LN fatty hilums (0%); however, those of VAHL and EqHL did (15.8 and 36%, respectively). After the logistic regression analysis of the patients who had axillary lymphadenopathy without any LN fatty hilums, the minor axis length and ellipticity (minor axis/major axis) in the largest axillary LN, SUVmax, and Tissue-to-Background Ratio (TBR) were useful in distinguishing malignant lymphadenopathies. A receiver-operating characteristic (ROC) analysis indicated that a cut-off value of ≥7.3 mm for the axillary LN minor axis (sensitivity: 0.714, specificity: 0.684) and of ≥0.671 for ellipticity (0.667 and 0.773, respectively) in the largest LN with the highest SUVmax and TBR were predictive of MHL. Conclusions: Axillary lymphadenopathy of the minor axis and ellipticity in LN without fatty hilums may be useful to be suspicious for malignancy, even in patients who have received COVID-19 vaccination. Further examinations, such as 18F-FDG PET, are recommended for such patients.

What problem does this paper attempt to address?

The paper attempts to address the issue of differentiating between axillary lymphadenopathy that occurs after receiving a COVID-19 vaccination and malignant lymphadenopathy. Specifically, the researchers aim to distinguish vaccine-induced reactive axillary lymphadenopathy (VAHL) from malignant hypermetabolic axillary lymphadenopathy (MHL) using clinical imaging methods such as ultrasound, CT, and 18F-FDG PET. ### Main Research Objectives: 1. **Distinguish VAHL and MHL**: Identify features that can effectively differentiate these two types of lymphadenopathy by analyzing clinical imaging data. 2. **Determine Diagnostic Indicators**: Establish specific imaging parameter thresholds (e.g., short-axis length, ellipticity, maximum standardized uptake value SUVmax, and tissue background ratio TBR) through statistical analysis to improve diagnostic sensitivity and specificity. ### Research Background: - **Side Effects of COVID-19 Vaccination**: Some patients develop axillary lymphadenopathy after receiving a COVID-19 vaccination, possibly due to vaccine-induced antigen migration. - **Clinical Significance**: Differentiating reactive lymphadenopathy from malignant lymphadenopathy is crucial for patients with a history of cancer or suspected cancer, as it directly impacts subsequent treatment decisions. ### Research Methods: - **Patient Selection**: A retrospective analysis was conducted on 1,096 patients who underwent PET-CT at Ehime University Hospital between June 1, 2021, and April 30, 2022, of which 188 patients had axillary lymphadenopathy. - **Grouping**: Patients were divided into three groups: VAHL group (27 cases), MHL group (21 cases), and equivocal hypermetabolic axillary lymphadenopathy group (EqHL group, 140 cases). - **Imaging Analysis**: Detailed analysis of lymph node morphology and metabolic activity was performed using ultrasound, CT, and 18F-FDG PET. ### Main Results: - **Gender Distribution**: The MHL group had a higher proportion of females (90.5%), mainly due to a higher incidence of breast cancer (80.9%). - **Presence of Fatty Hilum**: No fatty hilum was found in the lymph nodes of the MHL group (0%), whereas 15.8% and 36% of lymph nodes in the VAHL and EqHL groups, respectively, contained fatty hilum. - **Imaging Parameters**: Multivariate analysis revealed that short-axis length and ellipticity are important indicators for distinguishing MHL. Specifically, lymph nodes with a short-axis length ≥7.3 mm and ellipticity ≥0.671 are more likely to be malignant. ### Conclusion: - **Differential Diagnosis**: Short-axis length and ellipticity of axillary lymph nodes can serve as important indicators for distinguishing reactive lymphadenopathy from malignant lymphadenopathy, especially in the absence of a fatty hilum. - **Further Examination Recommendations**: For patients with these characteristics, further examinations such as 18F-FDG PET are recommended to confirm the diagnosis. These research findings enable doctors to more accurately determine the nature of axillary lymphadenopathy, thereby providing more appropriate treatment plans for patients.

Distinguishing Axillary Lymphadenopathy after COVID-19 Vaccination from Malignant Lymphadenopathy

18F-FDG PET/CT in Histiocytic Necrotizing Lymphadenitis:Two Cases and Review of the Literature

Lymphadenitis Associated with Cat-Scratch Disease Simulating a Neoplasm: Imaging Findings with Histopathological Associations.

Morphological and Metabolic Criteria of COVID-19 Vaccine Associated Axillary Nodes on 18-Fluorodeouxyglucose PET/CT Imaging in Breast Cancer Patients

Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on 18F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine

Axillary Lymphadenopathy after COVID-19 Vaccination: Follow-up for Enlarged Lymph Nodes on MR Imaging

Lymphadenopathy post‐COVID‐19 vaccination with increased FDG uptake may be falsely attributed to oncological disorders: A systematic review

Ipsilateral Malignant Axillary Lymphadenopathy and Contralateral Reactive Lymph Nodes in a COVID-19 Vaccine Recipient With Breast Cancer

Widespread Reactive Lymphatic and Splenic FDG Avidity After mRNA COVID Vaccination

COVID-19 mRNA Vaccination–Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT

DOTATATE -Avid Bilateral Axilla and Subpectoral Lymphadenopathy Induced From COVID-19 mRNA Vaccination Visualized on PET/CT

Clinical Features and 18F-FDG PET/CT for Distinguishing of Malignant Lymphoma from Inflammatory Lymphadenopathy in HIV-infected Patients.

Kikuchi-Fujimoto-like lymphadenopathy following COVID-19 vaccine: diagnosis and management

Incidental Finding of Moderna COVID-19 Vaccination–Related Axillary Lymphadenopathy on 201Tl Myocardial Perfusion Imaging

Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT

Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination

Incidence, Timing, and Long-Term Outcomes of COVID-19 Vaccine-Related Lymphadenopathy on Screening Mammography

Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines

The Combination of Maximum Standardized Uptake Value and Clinical Parameters for Improving the Accuracy in Distinguishing Primary Mediastinal Lymphomas from Thymic Epithelial Tumors

Precautions for breast ultrasound examination following COVID-19 vaccination

Hypermetabolic Axillary Lymphadenopathy After Shingrix Vaccination for Varicella Zoster Virus